HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination (Q45858638)

17 December 2017

title

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination (English)

1 reference

17 December 2017

1 reference

Chan T

1

1 reference

17 December 2017

Sami A

2

1 reference

17 December 2017

El-Gayed A

3

1 reference

17 December 2017

Guo X

4

1 reference

17 December 2017

Xiang J

5

1 reference

17 December 2017

publication date

25 May 2006

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

19

1 reference

17 December 2017

page(s)

1391-1402

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302797

exact match

0 references

cites work

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Chemokines: a superfamily of chemotactic cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

The neu oncogene encodes an epidermal growth factor receptor-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Genetic immunization against neu/erbB2 transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

1 reference

7 January 2021

Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Enhanced Dendritic Cell Maturation by TNF- or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

DNA-based immunization by in vivo transfection of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Synthetic DNA delivery systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Dendritic cells injected via different routes induce immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302797

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302797

1 reference

17 December 2017

Dimensions Publication ID

1022121849

0 references

1 reference

17 December 2017